文献速递胸部肿瘤

晚期非小细胞肺癌:2018年胸部肿瘤学进展

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
PubMed 文献 · J Thorac Oncol · 2019-04-16

本文综述2018年晚期非小细胞肺癌(NSCLC)研究进展:免疫检查点抑制剂(ICI)作为一线治疗策略的适用范围扩大至不考虑组织学亚型并将ICI应用扩展至III期疾病,改变了患者预后;这一新一线标准使标准二线治疗出现空白,ICI治疗进展后 older combinations 可能再次成为标准治疗。在致癌基因 addicted NSCLC 中,下一代酪氨酸激酶抑制剂在EGFR和ALK阳性肿瘤中超越更成熟药物成为新标准治疗;获得性耐药机制已被报道,针对罕见基因组改变(主要为融合)的个体化治疗获批,并提出在日常临床实践中实施下一代测序的挑战。

要点

  • 2018年ICI成为晚期NSCLC一线治疗策略,不受组织学亚型限制,并扩展至III期疾病。
  • 新一代TKI在EGFR和ALK阳性肿瘤中超越成熟药物成为新标准治疗。
  • 针对罕见基因组改变(主要为融合)的个体化治疗获批,NGS日常实施面临挑战。

核心结论

  • 2018年晚期NSCLC研究使ICI作为一线治疗策略的适用范围和影响扩大,不考虑组织学亚型,并将ICI应用扩展至III期疾病,改变了所有这类患者的预后。
  • 这一新一线标准方法在标准二线治疗中留下空白,ICI治疗进展后 older combinations 可能再次成为标准治疗。
  • 在致癌基因 addicted NSCLC 中,下一代TKI在EGFR和ALK阳性肿瘤中超越更成熟药物成为新标准治疗。

研究设计与样本

  • 本文为2018年胸部肿瘤学进展综述,检索范围原文未报告。

主要发现

  • 2018年ICI作为一线治疗策略的适用范围扩大至不考虑组织学亚型,并将ICI应用扩展至III期疾病。
  • 下一代TKI在EGFR和ALK阳性肿瘤中超越更成熟药物成为新标准治疗。
  • 在接受下一代EGFR TKI治疗的患者中已报道获得性耐药机制,反映了 landscape 的多样性。
  • 针对非常罕见的基因组改变(主要为融合)的个体化治疗获批。

关键数值与推荐

  • 原文未报告具体数值标准或推荐等级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of histologic subtype, with ICI use extended to include stage III disease, shifting the prognosis of all these patients. This new standard first-line approach opens a gap in standard second-line treatment, and older combinations may again become standard of care after progression during treatment with an ICI. The characterization of predictive biomarkers, patient selection, the definition of strategies with ICI combinations upon progression during treatment with ICIs, as well as prospective evaluation of the efficacy of ICIs in subpopulations (such as patients with poor performance status or brain metastases) represent upcoming challenges in advanced thoracic malignancies. In oncogene-addicted NSCLC three major steps were taken during 2018: next-generation tyrosine kinase inhibitors have overtaken more established agents as the new standard of care in EGFR and ALK receptor tyrosine kinase gene (ALK)-positive tumors. Mechanisms of acquired resistance have been reported among patients treated with next-generation EGFR tyrosine kinase inhibitors, reflecting the diversity of the landscape. One major step forward was the approval of personalized treatment in very uncommon genomic alterations, mainly fusions. This raises a new question about the challenge of implementation of next-generation sequencing in daily clinical practice to detect new and uncommon genomic alterations and to capture the heterogeneity of the mechanisms of acquired resistance during treatment, as well as the need to extend research into new therapeutic strategies to overcome them.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Remon J, Ahn MJ, Girard N, et al. Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. J Thorac Oncol. 2019. PMID: 31002952. doi:10.1016/j.jtho.2019.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。